5
Participants
Start Date
January 31, 2012
Primary Completion Date
July 31, 2012
Study Completion Date
October 31, 2012
Budesonide / Formoterol
"Budesonide/ formoterol (B/F) 160/4.5 mcg per activation. Subject who met inclusion criteria will be have at each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of either Budesonide/formoterol (B/F) 160/4.5 mcg per activation (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
Placebo
"Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
Brigham and Women's Hospital, Boston
Collaborators (1)
AstraZeneca
INDUSTRY
Brigham and Women's Hospital
OTHER